Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy
Abstract
Strategies to improve efficacy and reduce side effects of immune checkpoint blockade (ICB) therapy are clinically relevant. Here, we described a transdermal cold atmospheric plasma (CAP)-mediated ICB therapy. Local delivery of CAP through hollow-structured microneedles as microchannels promote the release of tumor-associated antigens by CAP. The subsequent T cell-mediated immune response can be augmented by the immune checkpoint inhibitors delivered via microneedles, resulting in enhanced local and systemic anticancer immunity. The synergism between CAP and ICB integrated with microneedles provides a platform technique for cancer treatment and other diseases in a minimally invasive manner.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 06, 2020
- Source ID
- 10.1073/pnas.1917891117
Entities
People
- Di Wen
- Gianpietro Dotti
- Guojun Chen
- Hongjun Li
- Richard E. Wirz
- Yi Zeng
- Zejun Wang
- Zhen Gu
- Zhitong Chen
Organizations
- Air Force Office of Scientific Research
- National Institutes of Health
- University of California
- University of North Carolina